Stock listing
OTC:CHGCF Chugai Pharmaceutical Co., Ltd. Stock
US listing (OTC) of Chugai Pharmaceutical Co., Ltd. · home listing Tokyo:4519
Follow Chugai Pharmaceutical Co., Ltd. into a list and get an email when it puts out news.
Share price · OTC:CHGCF
$44.81 USD +0.49 (+1.1%)
Close on Nov 20, 2026
- Day range
- $44.81 – $44.81 USDNov 20, 2026
- Volume
- 561 sharesNov 20, 2026
- Market cap
- $73.74B USDAt the close on Nov 20, 2026 · price × 1.65B shares outstanding
- 52-week range
- $34.79 – $68.08 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $497,453 USDMedian day 8,993 shares · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| OTC:CHGCY | $22.26 USD | -0.20 (-0.9%) | 218,409 | $22.81 | $22.81 | $22.01 | $22.46 | Close on Nov 20, 2026 |
| OTC:CHGCF | $44.81 USD | +0.488 (+1.1%) | 561 | $44.81 | $44.81 | $44.81 | $44.32 | Close on Nov 20, 2026 |
| Frankfurt:CUP | €40.51 EUR | -0.67 (-1.6%) | — | €40.54 | €40.65 | €40.51 | €41.18 | Close on Nov 20, 2026 |
| Munich:CUP | €40.08 EUR | -1.67 (-4.0%) | — | €40.64 | €40.64 | €40.08 | €41.75 | Close on Nov 20, 2026 |
| Dusseldorf:CUP | €39.61 EUR | -1.17 (-2.9%) | — | €40.09 | €40.58 | €39.61 | €40.78 | Close on Nov 20, 2026 |
| Frankfurt:CUP0 | €19.50 EUR | -0.40 (-2.0%) | — | €19.50 | €19.50 | €19.50 | €19.90 | Close on Nov 19, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · OTC:CHGCF · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $43.66 | -1.465 | -3.2% | $42.63 | $43.73 | $42.63 | 10,900 | |
| $45.13 | +1.39 | +3.2% | $44.69 | $46.22 | $44.26 | 82,400 | |
| $43.74 | +0.03 | +0.1% | $43.04 | $43.74 | $43.04 | 2,000 | |
| $43.71 | -0.095 | -0.2% | $42.77 | $43.78 | $42.77 | 3,500 | |
| $43.80 | +1.547 | +3.7% | $43.84 | $43.84 | $42.94 | 22,700 | |
| $42.25 | +1.515 | +3.7% | $44.56 | $44.61 | $42.24 | 15,000 | |
| $40.74 | +0.08 | +0.2% | $43.34 | $43.37 | $40.74 | 7,600 | |
| $40.66 | -6.959 | -14.6% | $40.67 | $43.12 | $40.66 | 1,700 | |
| $47.62 | +2.20 | +4.8% | $47.62 | $47.62 | $37.17 | 4,548 | |
| $45.42 | +0.597 | +1.3% | $45.03 | $45.68 | $42.55 | 15,308 | |
| $44.82 | +2.487 | +5.9% | $42.43 | $44.87 | $42.41 | 2,900 | |
| $42.33 | +2.785 | +7.0% | $43.26 | $43.27 | $40.94 | 8,700 | |
| $39.55 | -1.252 | -3.1% | $40.04 | $40.04 | $39.55 | 3,329 | |
| $40.80 | -0.20 | -0.5% | $41.95 | $41.95 | $39.58 | 4,004 | |
| $41.00 | +1.475 | +3.7% | $38.70 | $42.22 | $38.70 | 19,356 | |
| $39.53 | -0.035 | -0.1% | $38.58 | $40.97 | $38.58 | 9,381 | |
| $39.56 | +2.935 | +8.0% | $39.55 | $40.57 | $38.54 | 14,503 | |
| $36.63 | -1.785 | -4.6% | $38.00 | $38.03 | $36.51 | 16,221 | |
| $38.41 | +0.367 | +1.0% | $38.41 | $38.52 | $37.23 | 13,275 | |
| $38.04 | +0.357 | +0.9% | $36.66 | $38.99 | $36.66 | 38,053 | |
| $37.69 | +0.51 | +1.4% | $35.51 | $39.29 | $35.51 | 9,024 | |
| $37.18 | -1.085 | -2.8% | $38.14 | $39.35 | $36.52 | 11,058 | |
| $38.26 | -0.398 | -1.0% | $37.29 | $38.53 | $37.29 | 10,199 | |
| $38.66 | -0.63 | -1.6% | $37.18 | $38.66 | $37.18 | 7,333 | |
| $39.29 | +1.02 | +2.7% | $39.18 | $39.43 | $38.73 | 19,276 | |
| $38.27 | +0.427 | +1.1% | $39.93 | $39.93 | $37.45 | 11,441 | |
| $37.84 | -2.707 | -6.7% | $40.00 | $40.00 | $37.84 | 11,821 | |
| $40.55 | +0.957 | +2.4% | $39.73 | $40.82 | $38.39 | 8,961 | |
| $39.59 | -0.86 | -2.1% | $37.49 | $39.72 | $36.37 | 7,972 | |
| $40.45 | -1.065 | -2.6% | $41.51 | $41.83 | $40.45 | 12,866 | |
| $41.52 | +0.718 | +1.8% | $40.96 | $43.18 | $40.68 | 8,444 | |
| $40.80 | -1.775 | -4.2% | $40.79 | $43.14 | $40.79 | 3,873 | |
| $42.57 | -0.645 | -1.5% | $41.80 | $42.57 | $40.69 | 5,584 | |
| $43.22 | -0.135 | -0.3% | $41.43 | $43.22 | $41.41 | 2,435 | |
| $43.35 | +1.74 | +4.2% | $44.20 | $44.74 | $41.70 | 16,519 | |
| $41.61 | -0.96 | -2.3% | $41.54 | $44.00 | $41.53 | 4,711 | |
| $42.57 | +7.307 | +20.7% | $41.72 | $44.42 | $41.72 | 7,239 | |
| $35.27 | -5.915 | -14.4% | $41.55 | $41.55 | $34.79 | 9,332 | |
| $41.18 | -2.06 | -4.8% | $40.13 | $41.72 | $40.13 | 10,323 | |
| $43.24 | +0.485 | +1.1% | $42.66 | $43.24 | $41.98 | 16,347 | |
| $42.76 | +2.903 | +7.3% | $41.63 | $42.76 | $41.63 | 8,449 | |
| $39.85 | -1.523 | -3.7% | $40.29 | $42.55 | $39.85 | 12,536 | |
| $41.38 | -2.355 | -5.4% | $42.75 | $43.57 | $41.38 | 20,134 | |
| $43.73 | +0.39 | +0.9% | $42.40 | $43.82 | $42.27 | 36,070 | |
| $43.34 | -0.66 | -1.5% | $46.18 | $46.18 | $43.31 | 11,476 | |
| $44.00 | +2.403 | +5.8% | $45.21 | $45.21 | $42.95 | 8,050 | |
| $41.60 | +0.195 | +0.5% | $41.93 | $43.15 | $41.60 | 7,579 | |
| $41.40 | -2.857 | -6.5% | $42.03 | $43.15 | $41.40 | 4,779 | |
| $44.26 | -0.148 | -0.3% | $43.10 | $44.84 | $43.10 | 27,790 | |
| $44.41 | +0.625 | +1.4% | $42.77 | $45.26 | $42.46 | 7,665 | |
| $43.78 | +0.90 | +2.1% | $44.87 | $44.87 | $42.03 | 6,358 | |
| $42.88 | +0.473 | +1.1% | $42.99 | $45.21 | $42.88 | 3,381 | |
| $42.41 | -2.478 | -5.5% | $42.25 | $43.60 | $42.25 | 4,078 | |
| $44.89 | +2.858 | +6.8% | $42.61 | $44.89 | $42.61 | 10,616 | |
| $42.03 | -1.057 | -2.5% | $42.74 | $44.11 | $42.03 | 5,357 | |
| $43.09 | +0.26 | +0.6% | $45.46 | $45.46 | $43.09 | 2,721 |
Splits
1 split · OTC:CHGCF · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 3-for-1 | Split |
- Ticker
- OTC:CHGCF
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Oct 27, 2026
Supplementary Materials Consolidated Financial Statements for the nine months ended September 30, 2026 (IFRS)
Latest earnings call · Jul 24, 2026
Chugai Pharmaceutical (Tokyo:4519) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Oct 27, 2026
Q3 2026 Earnings Presentation
Earnings · 32 slides
Latest news
Supplementary Materials Consolidated Financial Statements for the nine months ended September 30, 2026 (IFRS)
Oct 27, 2026
Closed $47.62 (+4.8%) on Oct 27, 2026
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the nine months ended September 30, 2026)
Oct 27, 2026
Closed $47.62 (+4.8%) on Oct 27, 2026
F. Hoffmann-La Roche Announces Third Quarter Sales 2026
Oct 22, 2026
Closed $42.33 (+7.0%) on Oct 22, 2026
Notice Regarding Discontinuation of Development of GYM329 (emugrobart) for Obesity, Return of License and Resumption of Development for SMA
Sep 28, 2026
Closed $40.45 (-2.6%) on Sep 28, 2026
Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors
Sep 9, 2026
Closed $41.38 (-5.4%) on Sep 9, 2026
Chugai and GSK Sign Exclusive License Agreement for Anti-Dengue Virus Antibody AID351
Aug 18, 2026
Closed $41.71 (-6.9%) on Aug 18, 2026
Chugai Announces 2026 2nd Quarter Results
Jul 27, 2026
Closed $43.43 (-10.2%) on Jul 27, 2026
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the six months ended June 30, 2026)
Jul 24, 2026
Closed $48.35 (+16.0%) on Jul 24, 2026
F. Hoffmann-La Roche Announces Half Year Results 2026
Jul 23, 2026
Closed $41.68 (-4.5%) on Jul 23, 2026
Chugai Files New Drug Application in Japan for Sparsentan for the Treatment of IgA Nephropathy
Jun 22, 2026
Closed $46.31 (+0.8%) on Jun 22, 2026
Chugai Pharmaceutical Co., Ltd. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 25 in the last 12 months · 31 in all · newest Oct 27, 2026 · oldest 2025
- Calls
- 9 calls with a replay · 9 with a transcript · latest Jul 24, 2026
- Decks
- 107 decks · latest Oct 27, 2026
Where Chugai Pharmaceutical Co., Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Tokyo:4519 中外製薬 · Home listing | Tokyo | Japan | JPY |
| OTC:CHGCY | OTC | United States | USD |
| OTC:CHGCF · This page | OTC | United States | USD |
| gettex:CUP | gettex | Germany | EUR |
| Frankfurt:CUP | Frankfurt | Germany | EUR |
| Tradegate:CUP | Tradegate | Germany | EUR |
| LS Exchange:857216 | LS Exchange | Germany | EUR |
| Lang & Schwarz:857216 | Lang & Schwarz | Germany | EUR |
| BMV:4519N | BMV | Mexico | MXN |
| Munich:CUP | Munich | Germany | EUR |
| Stuttgart:CUP | Stuttgart | Germany | EUR |
| Hamburg:CUP | Hamburg | Germany | EUR |
| Dusseldorf:CUP | Dusseldorf | Germany | EUR |
| gettex:CUP0 | gettex | Germany | EUR |
| Hanover:CUP | Hanover | Germany | EUR |
| BIVA:4519N | BIVA | Mexico | MXN |
| Frankfurt:CUP0 | Frankfurt | Germany | EUR |
| Munich:CUP0 | Munich | Germany | EUR |
Team and board
Officers
| Officer | Role |
|---|---|
| Osamu Okuda | Representative Director, President & CEO |
| Iwaaki Taniguchi | Director, Executive Vice President & CFO |
| Hitoshi Iikura | Director, Executive Vice President |
| Boris L. Zaïtra | Head of Corporate Business Development of Roche |
Board
| Director | Role |
|---|---|
| Boris L. Zaïtra | Head of Corporate Business Development of Roche |
| Hitoshi Iikura | Director, Executive Vice President |
| Iwaaki Taniguchi | Director, Executive Vice President & CFO |
| Masayoshi Higuchi | Audit & Supervisory Board Member (full-time) |
| Osamu Okuda | Representative Director, President & CEO |
| Shigehiro Yamada | Audit & Supervisory Board Member (full-time) |
| Teresa A. Graham | Director |
| Thomas Schinecker | Director |
Events
| Call | When | Status |
|---|---|---|
| Chugai Pharmaceutical (Tokyo:4519) Q2 2026 Earnings Call | Fri, Jul 24, 2026 · 3:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q1 2026 Earnings Call | Fri, Apr 24, 2026 · 5:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q4 2025 Earnings Call | Thu, Jan 29, 2026 · 3:30 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q3 2025 Earnings Call | Sat, Oct 25, 2025 · 5:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q2 2025 Earnings Call | Thu, Jul 24, 2025 · 4:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q4 2024 Earnings Call | Thu, Jan 30, 2025 · 3:30 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q3 2024 Earnings Call | Fri, Oct 25, 2024 · 5:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q2 2024 Earnings Call | Wed, Jul 24, 2024 · 4:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q1 2024 Earnings Call | Wed, Apr 24, 2024 · 5:00 AM ET | Replay |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 32 slides | Oct 27, 2026 |
| Q3 2026 Earnings Presentation | Earnings | 32 slides | Oct 27, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 34 slides | Jul 24, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 34 slides | Jul 24, 2026 |
| Technical Presentation (June 2026) | Technical | 45 slides | Jun 17, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 34 slides | Apr 24, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 53 slides | Jan 29, 2026 |
| Q2 2025 Earnings Presentation | Earnings | 47 slides | Jul 24, 2025 |
| souzoulabo slide | 6 slides | February 2025 | |
| FY2024 Earnings Presentation | Earnings | 56 slides | Jan 30, 2025 |
Show 50 decks
This page holds 50 of 107 decks. Open Decks
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the nine months ended September 30, 2026) | Oct 27, 2026 | Results | Tokyo Stock Exchange |
| Supplementary Materials Consolidated Financial Statements for the nine months ended September 30, 2026 (IFRS) | Oct 27, 2026 | Results | Tokyo Stock Exchange |
| F. Hoffmann-La Roche Announces Third Quarter Sales 2026 | Oct 22, 2026 | Other filings | Tokyo Stock Exchange |
| Notice Regarding Discontinuation of Development of GYM329 (emugrobart) for Obesity, Return of License and Resumption of Development for SMA | Sep 28, 2026 | Other filings | Tokyo Stock Exchange |
| CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the six months ended June 30, 2026) | Jul 24, 2026 | Interim report | Tokyo Stock Exchange |
| F. Hoffmann-La Roche Announces Half Year Results 2026 | Jul 23, 2026 | Interim report | Tokyo Stock Exchange |
Cap table
Built by 6ix from Chugai Pharmaceutical Co., Ltd.’s releases
- Common shares
- 1,679,057,667
- Fully diluted
- 1,679,057,667
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,679,057,667 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,679,057,667 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Boris L. Zaïtra | Head of Corporate Business Development of Roche · Since at least Mar 27, 2026 |
| Hitoshi Iikura | Director, Executive Vice President · Since at least Mar 27, 2026 |
| Iwaaki Taniguchi | Director, Executive Vice President & CFO · Since at least Mar 27, 2026 |
| Masayoshi Higuchi | Audit & Supervisory Board Member (full-time) · Since at least Nov 5, 2026 |
| Osamu Okuda | Representative Director, President & CEO · Since at least Sep 9, 2026 |
| Shigehiro Yamada | Audit & Supervisory Board Member (full-time) · Since at least Nov 5, 2026 |
| Teresa A. Graham | Director · Since at least Mar 27, 2026 |
| Thomas Schinecker | Director · Since at least Mar 27, 2026 |
Log in to ask 6ix AI your own questions about Chugai Pharmaceutical Co., Ltd.